Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Some aspects of treatment for cognitive impairments. Cyticolin: pharmacological characteristics, possible benefits, aspects of use

https://doi.org/10.14412/2074-2711-2015-4-65-70

Full Text:

Abstract

The paper reviews the data available in the literature on the pharmacokinetic and pharmacodynamic properties of cyticolin and its use in cognitive impairments (CIs).

It assesses trials investigating the effect of cyticolin on cognitive functions, including its possible role in increasing Sirtuin 1 (SIRT1) expression. The results of the latest multicenter trials of the drug used to treat dementia syndrome are analyzed in elderly patients with clinical presentations of mental confusion (the VITA trial) and mild vascular CIs (the IDEALE trial).

Cyticolin is able to potentiate neuroplasticity and is a natural precursor of phospholipids, mainly phosphotidylcholine that serves as a source of choline in the metabolic pathways of acetylcholine biosynthesis. The VITA and IDEALE have shown that the parenteral and oral administrations of cyticolin are effective and safe in the treatment of moderate vascular CIs and dementia with clinical presentations of mental confusion. Cyticolin therapy is used to reduce the risk of side effects and to delay of loss of the therapeutic effects of levodopa preparations. Cyticolin has been noted to have a positive effect on cognitive functions in patients with Alzheimer’s disease if it is used as an additional therapy.

About the Authors

N. V. Trofimova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation

A.Ya. Kozhevnikov Clinic of Nervous System Disorders,

11, Rossolimo St., Moscow 119021



I. S. Preobrazhenskaya
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation

A.Ya. Kozhevnikov Clinic of Nervous System Disorders,

11, Rossolimo St., Moscow 119021



References

1. Захаров ВВ, Парфенов ВА, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2015. 192 с. [Zakharov VV, Parfenov VA, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive disorders]. Moscow: Remedium; 2015. 192 p.]

2. Преображенская ИС. Легкие и умеренные когнитивные нарушения: клинические проявления, этиология, патогенез, подходы к лечению. Неврология, нейропсихиатрия, психосоматика. 2013;5(1):59-63. [Preobrazhenskaya IS. Mild and moderate cognitive impairments: clinical manifestations, etiology, pathogenesis, treatment approaches. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2013;5(1):59-63. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2013-2401

3. DiCarlo A, Baldereschi M, Amaducci L, et al. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. J Am Geriatr Soc. 2000 Jul;48(7):775-82.

4. Graham JE, Rockwood K, Beattie EL, et al Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997 Jun 21;349(9068):1793-6.

5. Захаров ВВ. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврологический журнал. 2006;(11):27–32. [Zakharov VV. National program for research on the epidemiology and therapy of cognitive disorders in the elderly («Prometheus»). Nevrologicheskii zhurnal. 2006;(11):27–32. (In Russ.)].

6. Яхно НН, Преображенская ИС, Захаров ВВ и др. Распространенность когнитивных нарушений при неврологических заболеваниях (анализ работы специализированного амбулаторного приема). Неврология, нейропсихиатрия, психосоматика. 2012;4(2):30-5. [Yakhno NN, Preobrazhenskaya IS, Zakharov VV, et al. Prevalence of cognitive impairments in neurological diseases: Analysis of the activities of a specialized outpatient reception office. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2012;4(2):30-5. (In Russ.)].

7. Яхно НН. Когнитивные расстройства в неврологической клинике. Неврологический журнал. 2005;11(Приложение 1):4–12. [Yakhno NN. Cognitive disorders in neurological clinic. Nevrologicheskii zhurnal. 2005;11(S1):4–12. (In Russ.)].

8. Яхно НН, Захаров ВВ, Локшина АБ и др. Деменции. Руководство для врачей. Москва: МЕДпресс-информ; 2011. 272 c. [Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii. Rukovodstvo dlya vrachei [Dementia. A guide for physicians]. Moscow: MEDpressinform; 2011. 272 p.]

9. Захаров ВВ. Медикаментозные и немедикаментозные методы коррекции когнитивных нарушений. Consilium Medicum. 2014;(2):24-9. [Zakharov VV. Medicamental and non-medicamental methods of correction of cognitive impairment. Consilium Medicum. 2014;(2):24-9. (In Russ.)].

10. Golomb J, Kluger A, Garrard P, Ferris S. Clinician's manual on mild cognitive impairment. London: Science Press Ltd; 2001. 56 p.

11. Левин ОС. Диагностика и лечение деменции в клинической практике. Москва: МЕДпресс-информ; 2010. 256 с. [Levin OS. Diagnosis and treatment of dementia in clinical practice. Moscow: MEDpress-inform; 2010. 256 p.]

12. Klein J. Membrane breakdown in acute and chronic neurodegeneration:focus on cholinecontaining phospholipids. J Neural Transm (Vienna). 2000;107(8-9):1027-63.

13. Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol. 2011 Mar 14;52 Suppl 2:S1-S62.

14. Парфенов ВА. Цитиколин при ишемическом инсульте – исследование ICTUS. Неврология, нейропсихиатрия, психосоматика. 2012;4(4):71-6. [Parfenov VA. Citicoline for ischemic stroke: ICTUS trial. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2012;4(4):71-6. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2012-426

15. Парфенов ВА. Цитиколин в лечении ишемического инсульта и сосудистых когнитивных нарушений. Неврология, нейропсихиатрия, психосоматика. 2009;1(3-4): 69-74. [Parfenov VA. Citicolin in the treatment of stroke and vascular cognitive disorders. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2009;1(3-4):69-74. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-

16. -59

17. Grieb P. Neuroprotective properties of citicoline: facts, doubts and unresolved issues. CNS Drugs. 2014 Mar;28(3):185-93. doi: 10.1007/s40263-014-0144-8.

18. Hurtado O, Moro MA, Cardenas A, et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol Dis. 2005 Mar;18(2):336-45.

19. Gutierrez-Fernandez M, Rodriguez-Frutos B, Fuentes B, et al. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int. 2012 Feb;60(3):310-7. doi: 10.1016/j.neuint.2011.12.015. Epub 2011 Dec 30.

20. Bellizzi D, Dato S, Cavalcante P, et al. Characterization of a bidirectional promoter shared between two human genes related to aging: SIRT3 and PSMD13. Genomics. 2007 Jan;89(1):143-50. Epub 2006 Oct 23.

21. Donmez G. Sirtuins as possible targets in neurodegenerative diseases. Curr Drug Targets. 2013 Jun 1;14(6):644-7.

22. Donmez G, Guarente L. Aging and disease: connections to sirtuins. Aging Cell. 2010 Apr;9(2):285-90. doi: 10.1111/j.1474-9726.2010.00548.x.

23. Ma CY, Yao MJ, Zhai QW, et al. SIRT1 suppresses self-renewal of adult hippocampal neural stem cells. Development. 2014 Dec;141(24):4697-709. doi: 10.1242/dev.117937.

24. Kim SH, Lu HF, Alano CC. Neuronal SIRT3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS One. 2011 Mar 1;6(3):e14731. doi: 10.1371/journal.pone.0014731.

25. D'Aquila P, Rose G, Panno ML, et al. SIRT3 gene expression: a link between inherited mitochondrial DNA variants and oxidative stress. Gene. 2012 Apr 15;497(2):323-9. doi: 10.1016/j.gene.2012.01.042. Epub 2012 Jan 27.

26. Zhang F, Wang S, Gan L, et al. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol. 2011 Nov;95(3):373-95. doi: 10.1016/j.pneurobio.2011.09.001. Epub 2011 Sep 10.

27. Donmez G, Wang D, Cohen D, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell. 2010 Jul 23;142(2):320-32. doi: 10.1016/j.cell.2010.06.020.

28. Donmez G, Outeiro TF. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med. 2013 Mar;5(3):344-52. doi: 10.1002/emmm.201302451. Epub 2013 Feb 18.

29. Min SW, Cho SH, Zhou Y, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010 Sep 23;67(6):953-66. doi: 10.1016/j.neuron.2010.08.044.

30. Donmez G. The neurobiology of sirtuins and their role in neurodegen-eration. Trends Pharmacol Sci. 2012 Sep;33(9):494-501. doi: 10.1016/j.tips.2012.05.007. Epub 2012 Jun 30.

31. Albensi BC, Mattson MP. Evidence for the involvement of TNF and NF-kB in hippocampal synaptic plasticity. Synapse. 2000 Feb;35(2):151-9.

32. Donmez G, Arun A, Chung CY, et al. SIRT1 protects against a-synuclein aggregation by activating molecular chaperones. J Neurosci. 2012 Jan 4;32(1):124-32. doi: 10.1523/JNEUROSCI.3442-11.2012.

33. Polito L, Kehoe PG, Davin A, et al. The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian case control cohorts. Alzheimers Dement. 2013 Jul;9(4):392-9. doi: 10.1016/j.jalz.2012.02.003. Epub 2012 May 30.

34. Hurtado O, Hernandez-Jimenez M, Zarruk JG, et al. Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke. Alzheimers Dement. 2013 Jul;9(4):392-9. doi: 10.1016/j.jalz.2012.02.003. Epub 2012 May 30.

35. Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013;8:131-7. doi: 10.2147/CIA.S38420. Epub 2013 Feb 5.

36. Putignano S, Gareri P, Castagna A, et al. Retrospective and observational study to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome. Clin Interv Aging. 2012;7:113-8. doi: 10.2147/CIA.S29366. Epub 2012 May 10.

37. Caamargo J, Gumes MJ, Franco A, Cacabelos R. Effects of citicoline on cognition and cerebral hemodynamics in patients with Alzheimer's disease. Methods Find. Methods Find Exp Clin Pharmacol. 1994 Apr;16(3):211-8.

38. Fernandes-Novoa L, Alvares XA, Franco-MasideA, et al. CDP-choline-induced blood histamine changes in Alzheimer's disease. Methods Find Exp Clin Pharmacol. 1994 May;16(4):279-84.

39. Franco-Maside A, Caamano J, Gomez MJ, Cacabelos R. Brain mapping activity and mental performance after chronic treatment with CDPcholine in Alzheimer's disease. Methods Find Exp Clin Pharmacol. 1994 Oct;16(8):597-607.

40. Agnoli A, Ruggieri S, Denaro A, Bruno G. New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-cholin). Neuropsychobiology. 1982;8(6):289-96.

41. Eberhardt R, Birbamer G, Gerstenbrand F, et al. Citicoline in the treatment of Parkinson's disease. Clin Ther. 1990 Nov-Dec;12(6):489-95.

42. D'Orlando KJ, Sandage BW Jr. Citicoline (CDP-choline): mechanism of action and effects in ischemic brain injury. Neurol Res. 1995 Aug;17(4):281-4.

43. Dinsdale JR, Griffiths GK, Castello J, et al. CDP-choline: repeated oral dose tolerance studies in adult healthy volunteers. Arzneimittelforschung. 1983;33(7A):1061-5.

44. Lozano-Fernandez R. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2,817 cases. Arzneimittelforschung. 1983;33(7A):1073-80.


For citation:


Trofimova N.V., Preobrazhenskaya I.S. Some aspects of treatment for cognitive impairments. Cyticolin: pharmacological characteristics, possible benefits, aspects of use. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(4):65-70. (In Russ.) https://doi.org/10.14412/2074-2711-2015-4-65-70

Views: 353


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)